RT Journal Article SR Electronic T1 Human cardiac stromal cells exposed to SARS-CoV-2 evolve into hyper-inflammatory/pro-fibrotic phenotype and produce infective viral particles depending on the levels of ACE2 receptor expression JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.11.06.20226423 DO 10.1101/2020.11.06.20226423 A1 Amendola, Alessandra A1 Garoffolo, Gloria A1 Songia, Paola A1 Ferrari, Silvia A1 Bernava, Giacomo A1 Canzano, Paola A1 Myasoedova, Veronika A1 Colavita, Francesca A1 Castilletti, Concetta A1 Sberna, Giuseppe A1 Capobianchi, Maria Rosaria A1 Agrifoglio, Marco A1 Colombo, Gualtiero I. A1 Poggio, Paolo A1 Pesce, Maurizio YR 2020 UL http://medrxiv.org/content/early/2020/11/10/2020.11.06.20226423.abstract AB Patients with severe respiratory syndrome caused by SARS-CoV-2 undergo cardiac complications due to hyper-inflammatory conditions. Although the presence of the virus has been detected in the myocardium of infected patients, and infection of cardiac cells may involve ACE2 receptor, the underlying molecular/cellular mechanisms are still uncharacterized. We analyzed expression of ACE2 receptor in primary human cardiac stromal cells using proteomic and transcriptomic methods before exposing them to SARS-CoV-2 in vitro. Using conventional and high sensitivity PCR methods, we measured virus production in the cellular supernatants and monitored the intracellular viral bioprocessing. We performed high-resolution imaging to show the sites of intracellular viral production. We finally used Q-RT-PCR assays to detect genes linked to innate immunity and fibrotic pathways coherently regulated in cells exposed to virus. Our findings indicate that human cardiac stromal cells have a susceptibility to SARS-CoV-2 infection and produce variable viral yields depending on the extent of cellular ACE2 receptor expression. Interestingly, these cells also evolved toward hyper-inflammatory/pro-fibrotic phenotypes independently of ACE2 levels, suggesting a dual cardiac damage mechanism that could account for the elevated numbers of cardiac complications in severe COVID-19 cases.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementThis work has been financed by a Grant from Regione Lombardia (POR FESR 2014-2020-LINEA 2A COVID-grant no. 1850333) granted to M.P. and A.A. M.P. and A.A. are supported by Institutional grants (Ricerca Corrente, 5 per 1000) issued by Italian Ministry of Health. A.A. was supported also by COVID-2020-12371817 and COVID-2020-12371675 program grants from Italian Ministry of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Derivation of cells from human atrial appendage was approved by the Ethical Committee at Centro Cardiologico Monzino, IRCCS, Milano. A written agreement was obtained by each patient before collection of the material, during routine cardiac surgery interventions.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will made available at a public data repository upon request after publication.